NASDAQ OMX

CrownBio Enters Partnership with Pierre Fabre to Accelerate Discovery and Development of Immuno-Oncology Agents

Dela

SAN DIEGO, June 19, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience, a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announces that it has been selected by Pierre Fabre Research Institute as one of their partners to advance their immuno-oncology drug discovery pipeline.

CrownBio boasts the world's largest collection of patient-derived xenograft (PDX) models and is a leading provider of humanized solutions for immuno-oncology drug development. Leveraging these exclusive capabilities, CrownBio will engraft PDX models selected by Pierre Fabre into CD34+ humanized mouse models. These customized, humanized models will be used to accelerate Pierre Fabre's innovative immuno-oncology drug discovery pipeline.

"Pierre Fabre recognizes the value of CrownBio's extensive PDX collection and their expertise in implementing innovative humanization strategies," said Nathalie Corvaia, Pierre Fabre's Head of New Biologic Entity Platform and Director of Center of Immunology R&D Pierre Fabre. "We have chosen them as our partner for these reasons and look forward to what we are confident will be a successful alliance."  

"We are very pleased that Pierre Fabre has selected us as a trusted partner to advance their cutting-edge immuno-oncology pipeline," said Jean-Pierre Wery, CrownBio's CEO. "Our unique capabilities will enable Pierre Fabre to continue providing new and improved therapies for the treatment of cancer."

About Crown Bioscience Inc.

CrownBio is a global drug discovery and development solutions company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, CrownBio enables clients to deliver superior clinical candidates.

Media Enquiries:

Jody Barbeau
Crown Bioscience Inc. 
marketing@crownbio.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Crown Bioscience Inc. via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från NASDAQ OMX

Taconic Biosciences and Cyagen Biosciences Announce Strategic Partnership18.7.2018 14:00Pressmeddelande

RENSSELAER, N.Y., July 18, 2018 (GLOBE NEWSWIRE) -- Taconic Biosciences and Cyagen Biosciences, global leaders in the generation of custom genetically engineered rodent models and associated services, announced a strategic partnership. Under the agreement terms, the two companies will combine resources to provide the global scientific community with access to premium custom model design and generation services backed by comprehensive capabilities and cutting-edge, fully-licensed technologies. Custom animal models play a critical role in new drug discovery as biological systems that provide critical insight into the dynamic between a potential therapeutic and a living organism. Combining over twenty years of experience, the industry's most extensive model generation technology portfolio, and seamless integration to downstream premium custom breeding solutions, Taconic is recognized for creating complex genetically engineered mice and rats for biomedical research. Cyagen entered the indu

Data to be Presented From Biogen's Alzheimer's Disease Clinical Development Portfolio at the 2018 Alzheimer's Association International Conference (AAIC)18.7.2018 13:30Pressmeddelande

Ongoing Alzheimer's disease research programs target possible causes of the disease through multiple modalities Data to be presented from Alzheimer's disease clinical development portfolio including aducanumab, elenbecestat, and BAN2401 Data underscore Biogen's long-term commitment to furthering Alzheimer's disease research and treatment, with a focus on patients with early stage disease CAMBRIDGE, Mass., July 18, 2018 (GLOBE NEWSWIRE) -- Biogen (Nasdaq:BIIB) announced it will present data from its Alzheimer's disease clinical development portfolio at the upcoming Alzheimer's Association International Conference (AAIC) in Chicago (July 22-26). Data being presented are part of Biogen's research programs targeting several of the identified causes of Alzheimer's disease, focusing on early-stage disease. "The data to be presented at AAIC exemplify our belief that treatments are needed at the earliest stages of Alzheimer's disease to impact the underlying pathophysiology and delay disease p

SEMAFO Provides Notice of Second Quarter 2018 Results Release and Conference Call18.7.2018 13:00Pressmeddelande

MONTREAL, July 18, 2018 (GLOBE NEWSWIRE) -- SEMAFO (TSX:SMF)(OMX:SMF) invites you to participate in a conference call on August 8, 2018 at 08:00 AM EST with senior management during which they will review the Corporation's second quarter 2018 financial and operational results. SEMAFO's financial statements and management's discussion and analysis for the second quarter 2018 will be released on August 7 following TSX close and will be available in the "Investor Relations" section of the Corporation's website at www.semafo.com , and on the Canadian Securities Administrators' website at www.sedar.com . A live audio webcast of the conference call will be accessible for a period of 30 days through SEMAFO's website at www.semafo.com . Tel. local & overseas: +1 (647) 788 4922 Tel. North America: 1 (877) 223 4471 Webcast: www.semafo.com Replay overseas: +1 (416) 621 4642 Replay N. America: 1 (800) 585 8367 Replay pass code: 7370499 Expiration: September 08, 2018 About SEMAFO SEMAFO is a Canadi

Compuware Acquires XaTester and Partners with Parasoft to Deliver Essential Automated Unit Testing to Mainframe DevOps Teams18.7.2018 12:00Pressmeddelande

Topaz Further Established as the Leading Solution for Continuously Improving Velocity, Quality and Efficiency of Enterprise Systems Large enterprises must rigorously safeguard the quality of their mission-critical mainframe systems as digital demands drive them to develop and deploy mainframe code more quickly and frequently. With the acquisition of XaTester, new enhancements, and partnership with Parasoft, Compuware Topaz for Total Test is the clear leader in the automated unit testing essential for Agile and DevOps on the mainframe. With Topaz, developers at all skill levels can quickly and efficiently produce the highest-quality code for the mainframe-enabling enterprises to achieve the digital agility essential for success in fast-moving markets. DETROIT, July 18, 2018 (GLOBE NEWSWIRE) -- Compuware today announced a product acquisition, enhancements to Topaz for Total Test, and a partnership that together dramatically improve the ability of large enterprises to embrace Agile and De

Cryptomining Replaces Ransomware as Most Popular Cybercrime Malware18.7.2018 09:00Pressmeddelande

Analysis of vulnerability and threat trends shows cryptomining malware dominates threat landscape in the first half of 2018 SAN JOSE, Calif., July 18, 2018 (GLOBE NEWSWIRE) -- Skybox® Security, a global leader in cybersecurity management, announced today the release of its mid-year update to the Vulnerability and Threat Trends Report which analyzes vulnerabilities, exploits and threats in play. The report, compiled by the team of security analysts at the Skybox® Research Lab, aims to help organizations align their security strategy with the reality of the current threat landscape. The mid-year update explores trends observed from January to June of 2018. One of the most significant findings is the replacement of ransomware as the cybercriminal tool of choice with cryptomining malware. In the last six months of 2017, ransomware accounted for 32 percent of attacks, while malicious cryptominers accounted for seven percent. By the first half of 2018, the figures had switched almost exactly

GridGain® Continues In-Memory Computing Industry Leadership in 201818.7.2018 09:00Pressmeddelande

GridGain Continues Rapid Growth, Delivers Product Innovations, Hosts Vital Industry Conferences and Earns Top Industry Accolades FOSTER CITY, Calif., July 18, 2018 (GLOBE NEWSWIRE) -- GridGain® Systems, provider of enterprise-grade in-memory computing solutions based on Apache® Ignite(TM), today announced continuing strong momentum for the first half of 2018. Key achievements during the first half of the year included more new customer wins in the first half of 2018 than in all of 2017, launching major new products including GridGain Professional Edition 2.4 and GridGain Cloud, winning several top industry accolades, and driving continued growth of the popular In-Memory Computing Summit® in Europe. Growth New customer acquisition surged during the first half of 2018 with the company acquiring 40 percent more new customers than were signed in all of 2017. New customers acquired in 2018 include leading companies in financial services, transportation, telecommunications, retail, healthcar

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum